Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.
about
Nanotechnology-based strategies for treatment of ocular disease.Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Nanocrystal for ocular drug delivery: hope or hype.Primary angle closure glaucoma (PACG) susceptibility gene PLEKHA7 encodes a novel Rac1/Cdc42 GAP that modulates cell migration and blood-aqueous barrier function.Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.Lipid core nanoparticles resembling low-density lipoprotein and regression of atherosclerotic lesions: effects of particle size.Nanotechnology in retinal drug delivery.
P2860
Q33681543-F1909C0F-92D0-4969-A59A-8BBD80F688F6Q36384149-1341BC9A-3070-4A1C-AC6C-21B5AD166FF3Q38831205-4DF63AD9-1A02-4A95-A918-CED053C1BAF5Q47670930-5CAA6B55-7883-447E-9503-A5C5485CA41CQ49996892-967555F1-6E06-4314-927F-EA4F9C476323Q51743444-53D84217-A2D2-44A9-B49E-1A6CAE536060Q55491207-5094ED5C-F1E2-4CA9-9685-C98E9B76AA57
P2860
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.
@en
type
label
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.
@en
prefLabel
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.
@en
P2093
P2860
P1433
P1476
Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems
@en
P2093
Fatima R Freitas
Raul C Maranhao
Vital P Costa
P2860
P304
P356
10.3390/PHARMACEUTICS4020252
P577
2012-05-14T00:00:00Z